MetLife Investment Management’s Intra-Cellular Therapies Inc. ITCI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-6,329
| Closed | -$835K | – | 2956 |
|
|
2025
Q1 | $835K | Sell |
6,329
-14
| -0.2% | -$1.75K | ﹤0.01% | 1452 |
|
|
2024
Q4 | $530K | Sell |
6,343
-145
| -2% | -$11.9K | ﹤0.01% | 1766 |
|
|
2024
Q3 | $475K | Sell |
6,488
-127
| -2% | -$9.54K | ﹤0.01% | 1814 |
|
|
2024
Q2 | $453K | Sell |
6,615
-41,388
| -86% | -$2.87M | ﹤0.01% | 1774 |
|
|
2024
Q1 | $3.32M | Sell |
48,003
-1,367
| -3% | -$94K | 0.02% | 724 |
|
|
2023
Q4 | $3.54M | Hold |
49,370
| – | – | 0.03% | 679 |
|
|
2023
Q3 | $2.57M | Hold |
49,370
| – | – | 0.02% | 786 |
|
|
2023
Q2 | $3.13M | Buy |
49,370
+1,499
| +3% | +$93.4K | 0.02% | 727 |
|
|
2023
Q1 | $2.59M | Sell |
47,871
-846
| -2% | -$40.9K | 0.02% | 815 |
|
|
2022
Q4 | $2.58M | Hold |
48,717
| – | – | 0.02% | 789 |
|
|
2022
Q3 | $2.27M | Buy |
48,717
+1,135
| +2% | +$59.3K | 0.02% | 825 |
|
|
2022
Q2 | $2.72M | Buy |
47,582
+5,067
| +12% | +$287K | 0.02% | 772 |
|
|
2022
Q1 | $2.6M | Buy |
42,515
+18,160
| +75% | +$943K | 0.02% | 884 |
|
|
2021
Q4 | $1.27M | Sell |
24,355
-2,111
| -8% | -$88.7K | 0.01% | 1031 |
|
|
2021
Q3 | $987K | Hold |
26,466
| – | – | 0.01% | 1122 |
|
|
2021
Q2 | $1.08M | Hold |
26,466
| – | – | 0.01% | 1119 |
|
|
2021
Q1 | $898K | Hold |
26,466
| – | – | 0.01% | 1208 |
|
|
2020
Q4 | $842K | Hold |
26,466
| – | – | 0.01% | 1211 |
|
|
2020
Q3 | $679K | Hold |
26,466
| – | – | 0.01% | 1220 |
|
|
2020
Q2 | $679K | Buy |
26,466
+3,201
| +14% | +$64.8K | 0.01% | 1213 |
|
|
2020
Q1 | $358K | Buy |
23,265
+3,659
| +19% | +$79.5K | ﹤0.01% | 1392 |
|
|
2019
Q4 | $673K | Hold |
19,606
| – | – | 0.01% | 1294 |
|
|
2019
Q3 | $146K | Hold |
19,606
| – | – | ﹤0.01% | 2117 |
|
|
2019
Q2 | $254K | Hold |
19,606
| – | – | ﹤0.01% | 1889 |
|
|
2019
Q1 | $239K | Hold |
19,606
| – | – | ﹤0.01% | 1885 |
|
|
2018
Q4 | $223K | Hold |
19,606
| – | – | ﹤0.01% | 1846 |
|
|
2018
Q3 | $425K | Hold |
19,606
| – | – | ﹤0.01% | 1632 |
|
|
2018
Q2 | $346K | Hold |
19,606
| – | – | ﹤0.01% | 1631 |
|
|
2018
Q1 | $413K | Buy |
19,606
+2,613
| +15% | +$50.9K | ﹤0.01% | 1479 |
|
|
2017
Q4 | $246K | Buy |
+16,993
| New | +$262K | ﹤0.01% | 1822 |
|
Other funds holding ITCI
KIM
HNB
MetLife Investment Management's ITCI Position: Q2 2025 in Review
MetLife Investment Management sold out of Intra-Cellular Therapies Inc. (ITCI) in Q2 2025, closing a stake of 6,329 shares — an estimated $835K sold.
MetLife Investment Management first reported a position in ITCI in Q4 2017 and held it in 30 quarters. The position peaked at $3.54M in Q4 2023. 4 funds tracked by Wall St. Rank hold ITCI as of Q2 2025.
- MetLife Investment Management reported no remaining Intra-Cellular Therapies Inc. position as of Q2 2025 after selling out during the quarter.
- MetLife Investment Management sold 6,329 Intra-Cellular Therapies Inc. shares in Q2 2025, an estimated $835K.
- MetLife Investment Management first reported a position in Intra-Cellular Therapies Inc. in Q4 2017 and held it in 30 quarters.
- MetLife Investment Management's Intra-Cellular Therapies Inc. position peaked at $3.54M in Q4 2023.
- 4 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q2 2025.
Based on MetLife Investment Management's 13F filing for Q2 2025, filed 13 Aug 2025.